Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Nordea Kredit Realkreditaktieselskab – Interim Report January-June 2021 Company announcement no 74, 2021

Nordea Kredit Realkreditaktieselskab today presented the attached Interim Report January-June 2021 with the following key points: · Nordea Kredit continued to see high activity levels in the first half of 2021, particularly driven by properties with a change of ownership for household customers. · Nordea Kredit continued to develop its sustainability offering and has as per end-June 2021 issued DKK 9bn in green mortgages for corporate customers. · Nordea Kredit has continuously increased its market share within owner-occupied dwellings during the past five quarters. · Lending

Calliditas Therapeutics and STADA partner to register and commercialize specialty therapy for IgA Nephropathy in Europe

· Calliditas and STADA partner to bring a specialty therapy focused on downregulating IgA1 to European patients. If approved, it would be the first-ever approved treatment in the EU for chronic autoimmune kidney disease IgA Nephropathy (IgAN) · Partnership for this oral orphan-drug candidate combines Calliditas’ drug-delivery expertise with STADA’s pan-European marketing and sales expertise, including for specialty and nephrology medicines · Deal covering European Economic Area (EEA) member states, Switzerland and the UK is valued at a total of 97.5 million EUR ($115m), plus royalties

Prevas: interim report January – June 2021

Strong quarter and first six months.April – June · Net turnover 313.2 MSEK (194.0) · Operating profit/loss EBITA 29.8 MSEK (14.6) · Operating margin EBITA 9.5 % (7.5) · Profit after tax 17.5 MSEK (11.3) · Profit per share 1.35 SEK (1.14) January – June · Net turnover 614.1 MSEK (410.3) · Operating profit/loss EBITA 61.3 MSEK (36.8) · Operating margin EBITA 10.0 % (9.0) · Profit after tax 40.4 MSEK (27.9) · Profit per share 3.10 SEK (2.80)  A word from the CEO Strength in progress. Strong quarter and first six months The year's good

IRRAS receives extension of its MDSAP certification and scope expansion of MDSAP & ISO 13485:2016 certifications

· After completion of successful verification audit by its notified body DEKRA, IRRAS’ Medical Device Single Audit Program (MDSAP) certification has been extended for three years until July 2024 · The company’s MDSAP/ISO 13485:2016 certification will also have a scope upgrade to include company’s new manufacturing facility following the audit’s site inspection · The expanded ISO certification now allows product manufactured in IRRAS’ new facility to be shipped globallyStockholm, July 21, 2021 – IRRAS AB, a commercial-stage medical technology company with a comprehensive portfolio of

Update on a new clinical Phase Ib trial for the RH5.1 blood-stage malaria vaccine

Hørsholm, Denmark, July 21, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that University of Oxford has initiated the VAC080-study, a Phase Ib clinical trial to assess the safety and immunogenicity of the blood-stage Plasmodium falciparum malaria vaccine candidate RH5.1/Matrix-M in adults and infants living in Tanzania.The RH5.1 blood-stage malaria protein vaccine has previously been administered to 67 healthy UK adults, with various doses, and was found to be safe and well tolerated. The study is estimated to be completed in H2

Transactions in connection with share buy-back programme

On 4 March 2021, H+H International A/S (hereinafter referred to as “H+H” or “the Company”) initiated a share buy-back programme in compliance with Article 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on Market Abuse and Commission Delegated Regulation (EU) 1052/2016 of 8 March 2016 (the “Safe Harbour Regulation”). On 18 March 2021, the share buy-back programme was increased by DKK 15 million, thereby increasing the maximum aggregate purchase price of the shares to be bought back under the programme to DKK 115 million. The share buy-back

Kindred’s revenue from harmful gambling amounted to 4.3 per cent

Kindred continue to focus on contributing to a more sustainable gambling market through an open and fact-based discussion across industry stakeholders. In the second quarter of 2021, Kindred’s share of revenue from harmful gambling increased slightly to 4.3 per cent.In February this year, Kindred Group plc (Kindred) started to communicate about its “Journey towards zero” by announcing the share of revenue derived from harmful gambling. Kindred has set an ambition to reach zero per cent of revenue from harmful gambling by the end of 2023 and report this on a quarterly basis. The purpose is

Sobi publishes report for the second quarter 2021

Swedish Orphan Biovitrum AB (publ)  (Sobi™) today announces its results for the second quarter 2021. Total revenue amounted to SEK 3,211 M, 14 per cent growth at CER compared with the same period 2020. EBITA was SEK 922 M, resulting in an EBITA margin of 29 per cent. April – June · Total revenue of SEK 3,211 M (3 070), 5 per cent growth and 14 per cent at CER · EBITA[1] was SEK 922 M (1,018), with an EBITA margin[1] of 29 per cent (33) · Earnings per share (EPS) before dilution of SEK 0.91 (0.96) · Haematology sales were SEK 2,125 M (2,037), 12 per

Latest data on lecanemab to be presented at Alzheimer’s Association International Conference (AAIC)

Stockholm, July 21, 2021 - BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will hold several presentations at the Alzheimer’s Association International Conference (AAIC) to be held in Denver, Colorado and virtually from July 26 to 30, 2021. The presentations will include the latest data of the investigational anti-amyloid beta (Aβ) protofibril selective antibody lecanemab (BAN2401) for which the FDA has granted Breakthrough Therapy designation.The presentations regarding lecanemab include oral presentations about the preliminary assessment of the clinical effect of lecanemab

CONCENTRIC INTERIM REPORT JANUARY –JUNE 2021

SECOND QUARTER · Net sales: MSEK 473 (342) – reported sales were up +38% year-on-year. After adjusting for the impact of currency (–14%) and Allied Enterprises (+7%), sales in constant currency year-on-year were up +45%. · Operating income: MSEK 107 (28), generating an operating margin of 22.7% (8.3), operating margin before items affecting comparability was 22.7% (14.2). · Net income for the period: MSEK 85 (17); basic EPS of SEK 2.25 (0.44). · Cash flow from operating activities: MSEK 76 (87); cash generation has been affected by increases in working capital to support

Tikkurila to publish its half year financial report for 2021 on Friday July 23, 2021 at around 9.30 a.m.

Investor News21 July 2021, at 8.35 a.m. EEST Tikkurila Oyj will publish its half year financial report for 2021 on Friday, July 23, 2021 at approximately 9.30 a.m. (EET). Half year financial report for 2021 will be published in English and in Finnish as a stock exchange release. Materials can be found also on Tikkurila’s webpages www.tikkurilagroup.com under Investors after the publication. For further information, please contact:Tikkurila Communicationsir@tikkurila.com

Notice to the Annual General Meeting of Elekta AB (publ)

The shareholders of Elekta AB (publ), reg. no 556170–4015 are hereby convened to the Annual General Meeting to be held on Wednesday 25 August 2021.Due to the coronavirus pandemic, the Board of Directors has decided that the Meeting should be conducted without the physical presence of shareholders, representatives or third parties and that the shareholders before the meeting should be able to exercise their voting rights only by voting in advance, so-called postal voting. Information on the resolutions passed at the Meeting will be published on Wednesday 25 August 2021, as soon as the result

Evolution: Interim report January-June 2021

· Continued high demand for Live Casino +59% growth YoY · Announced acquisition of Big Time Gaming closed on June 30th · After the end of the period, the new Michigan studio was approved and is ready for launchSecond quarter of 2021 (Q2 2020) · Operating revenues increased by 100% to EUR 256.7 million (128.3) · EBITDA increased by 115% to EUR 174.7 million (81.1), corresponding to a margin of 68.0% (63.2) · Profit for the period amounted to EUR 144.4 million (70.4) · Earnings per share amounted to EUR 0.68 (0.39) January-June 2021 (1H 2020) · Operating revenues

SRV’s half-year financial report January–June 2021: Financing arrangements improve balance sheet and financing structure; favourable trends in profitability continue

SRV GROUP PLC     HALF-YEAR FINANCIAL REPORT     21 JULY 2021      8:30 EET SRV’s half-year financial report January–June 2021: Financing arrangements improve balance sheet and financing structure; favourable trends in profitability continue January–June 2021 in brief: · Revenue declined by 14.4 per cent to EUR 405.1 million (473.1 1−6/2020). · Operative operating profit improved to EUR 10.5 (4.9) million. · Operating profit was EUR 11.4 (7.8) million. · The result before taxes  was EUR 3.6 (-6.4) million. · Cash flow from business and investment activities totalled

Saab’s Results January-June 2021: Strong sales growth and positive cash flow

Saab presents the results for January-June 2021.Key highlights Q2 2021 · Orders increased 7% and the order backlog amounted to SEK 96.7bn. · Organic sales growth of 15% driven by high project activity and deliveries. · EBITDA increased 19% to SEK 1,196m (1,004), a margin of 11.8% (11.4). · Operating income improved 10% and amounted to SEK 715m (652), corresponding to a margin of 7.1% (7.4), including costs for right-sizing measures of SEK 85 million. · Operational cash flow was SEK 3,152m (1,817) due to large milestone payments received in the quarter. · New

Interim report Q2 2021

Hoist Finance’s second quarter was stable in terms of performance, but with limited growth. The market saw quite a lot of activity, but the competition was very high, leading to high-priced portfolios. The collection performance was solid at 102%. Without one-off effects, profit before tax was SEK 64m. “We need to focus and improve performance. We are initiating a transformation to accelerate portfolio acquisitions, improve productivity and reduce costs,” says Per Anders Fasth, CEO of Hoist Finance. April - June 2021 · Total operating income amounted to SEK 625m (513) · Profit/

Stora Enso’s pilot plant for producing lignin-based carbon materials for batteries is now operational

STORA ENSO OYJ INVESTOR NEWS 21 July 2021 at 8:30 EESTStora Enso’s pilot facility for producing bio-based carbon materials from lignin has started operations. This follows the company’s EUR 10 million investment announced in 2019. Pilot production of Lignode® by Stora Enso, wood-based carbon for batteries, is currently being ramped up. Applications include electric vehicles and consumer electronics as well as large-scale energy storage systems.The global battery market is projected to grow tenfold over the next decade as battery producers seek more sustainable materials for the

Report for the second quarter 2021: Historical quarter – Solid internal performance in a strong market

The second quarter · Revenue was SEK 23,673 (15,155) million · EBITDA was SEK 4,899 (705) million · Operating profit was SEK 4,083 (-251) million · Earnings per share were SEK 3.13 (-0.28)Comments by the CEO – a historical quarter for SSAB For Q2 2021, we report the highest quarterly operating profit ever, driven by strong demand, high steel prices and stable production. At the same time, we consolidated our position as the leading force in the green transition of the steel industry. The quarter saw us take groundbreaking steps towards full-scale fossil-free steelmaking and

Stora Enso Oyj Half-year Report January–June 2021

STORA ENSO OYJ HALF-YEAR FINANCIAL REPORT 21 July 2021 at 8.30 EESTStrong performance and solid growth continue Q2/2021 (year-on-year) · Sales increased by 22.6% to EUR 2 592 (2 114) million, due to higher deliveries and prices. · Operational EBIT increased to EUR 364 (178) million, due to higher prices and volumes, especially in Biomaterials, Wood Products, and Packaging Materials. · Operational EBIT margin increased to 14.0% (8.4%). · Operating profit (IFRS) decreased to EUR 182 (226) million. · EPS was EUR 0.26 (0.19) and EPS excl. fair valuations (FV) was EUR 0.27 (0.

Stora Enso and Tetra Pak join forces to triple the recycling capacity of beverage cartons in Poland

STORA ENSO OYJ INVESTOR NEWS 21 July 2021 at 8:30 EESTThe two companies will partner to provide circular solutions to the market. The investment in a complete recycling solution is set to significantly improve recycling throughout Central and Eastern Europe.The partnership, that follows a comprehensive feasibility study, sees the introduction of a large-scale carton repulping line at Stora Enso’s Ostrołęka production unit in Poland. The line will triple the annual recycling capacity of used beverage cartons in Poland from 25 000 to 75 000 tonnes. This will allow recycling of the entire

Interim report for the second quarter and first half of 2021

Healthy orders received and continued earnings improvement“Operating profit is improving in the contracting operations. We experience healthy demand, strong letting in our development projects, but Industry can still improve,” says Tomas Carlsson, President and CEO of NCC. · A positive quarter for the contracting operations, with favorable orders received and higher operating profit · Industry demonstrated underlying improvements, but operating profit was weighted down by asphalt operations in Finland · Favorable letting in ongoing property development projects, no major projects

Alma Media’s Half-Year Report January–June 2021: Revenue and operating profit in the second quarter were significantly increased by strong business development and acquisitions

Alma Media Corporation   Half-Year Report    21 July 2021 at 8.00 a.m. ALMA MEDIA’S HALF-YEAR REPORT JANUARY–JUNE 2021: REVENUE AND OPERATING PROFIT IN THE SECOND QUARTER WERE SIGNIFICANTLY INCREASED BY STRONG BUSINESS DEVELOPMENT AND ACQUISITIONS. Financial performance April–June 2021: - Revenue MEUR 71.6 (52.6), up 36.1%. - The share of revenue represented by digital business was 77.6% (67.3%). - Adjusted operating profit MEUR 16.6 (9.8), up 69,2%. - Operating profit MEUR 13.0 (7.0), up 87,0%. - Earnings per share from continuing operations EUR 0.12 (0.04). - Alma

BERGENBIO COVID-19 DATA PRESENTED AT THE ANNUAL AMERICAN SOCIETY FOR VIROLOGY

Bergen, Norway, 21 July 2021 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that pre-clinical data evaluating bemcentinib, BerGenBio’s first-in-class, potent and highly selective AXL inhibitor, for the treatment of SARS-CoV-2 infection has been presented at the 40[th] Annual American Society for Virology (ASV). The presentation was given by BerGenBio’s collaborator, Mr. Dana Bohan, a PhD candidate from the University of Iowa, who outlined previously announced

Member of Neste Board of Directors resigns

Neste Corporation, Stock Exchange Release, 21 July 2021 at 8 a.m. (EET)Sonat Burman-Olsson, member of the Board of Directors of Neste Corporation, has announced her resignation from the Board of the company as of today. The reason for the resignation is her election as a member of the Board of Directors of the Brazilian energy company Raizen S.A.The Shareholders' Nomination Board of Neste has assessed that the Board will remain functional after Burman-Olsson's resignation, and that the Board's composition will continue to meet the requirements set out in the Articles of Association. The

There are no items matching the current filter
There are no more items matching the current filter
Back to top